Physician profile
Jack Collazzo
NPI 1891725891
$3,782.78
in general payments reported to CMS, 2019-2025
19 companies · $564 in 2025
The $564 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $666 · 2020: $427 · 2021: $877 · 2022: $870 · 2023: $173 · 2024: $206 · 2025: $564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $822 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $822.24 |
| Education | $119.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,871.18 | 2020-2025 | Linzess, Viberzi |
| Janssen Biotech, INC. | $290.04 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $261.72 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $214.64 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $198.26 | 2022 | |
| Paratek Pharmaceuticals, INC. | $122.90 | 2020 | |
| Alexion Pharmaceuticals, INC. | $120.82 | 2019 | |
| Gilead Sciences, INC. | $119.99 | 2023 | Epclusa |
| Janssen Scientific Affairs, LLC | $112.76 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $104.68 | 2019-2021 | |
| Shire North American Group INC | $101.93 | 2019 | |
| Pfizer INC. | $74.46 | 2019-2022 | |
| Celgene Corporation | $50.44 | 2022-2024 | Zeposia |
| Ucb, INC. | $37.77 | 2019-2020 | |
| Qol Medical, LLC | $25.53 | 2019-2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $21.49 | 2024 | Iqirvo |
| Intra-Sana Laboratories | $20.61 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Genzyme Corporation | $17.90 | 2024 | |
| Intercept Pharmaceuticals, INC. | $15.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Collazzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.